Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells.
Ontology highlight
ABSTRACT: Although androgen deprivation therapy (ADT) serves as the primary treatment option for localized or metastatic prostate cancer, most cases eventually develop into castration-resistant prostate cancer (CRPC). However, androgen receptor (AR) continues to be functional in CRPC through various mechanisms, including the development of AR splicing variants, especially ARV7. Since it lacks the ligand binding domain but retains the intact DNA binding domain, ARV7 is constitutively active, which makes ARV7-positive prostate cancer responsive to neither abiraterone nor enzalutamide. In this study, we explored the effect of resveratrol on ARV7 transcriptional activity and the potential for development of resveratrol as a treatment for ARV7-positive prostate cancer. First, we ectopically expressed ARV
SUBMITTER: Wilson S
PROVIDER: S-EPMC5589613 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA